Berbevis Dose-finding Study in Subjects With Impaired Fasting Glucose

ConditionImpaired Fasting Glucose (IFG)

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorAzienda di Servizi alla Persona di Pavia

About this trial

Assessing the effects of a nutraceutical supplement (Berbevis™) in adults with impaired fasting glucose (100-126 mg/dL) and BMI between 25 and 35. Ninety participants will be assigned to three parallel groups receiving Berbevis™ at increasing daily doses (500 mg, 750 mg, and 1000 mg) for 2 months.

Eligibility criteria

Qualifiers

fasting blood glucose between 100 and 126 mg/dl

BMI between 25 and 35 kg/m²

Disqualifiers

Fasting blood glucose below 100 mg/dl

BMI < 25 or > 35 kg/m²

Trial design

Treatments tested in this trial

Berbevis supplement

Treatment groups

90 Participants

are divided into 3 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Azienda di Servizi alla Persona di Pavia

Lead sponsor

Source ClinicalTrials.gov